Top

28-01-2018 | Cardiovascular disorders | Review | Article

Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach

Journal: Diabetologia

Authors: Giuseppe Mancia, Guido Grassi

Publisher: Springer Berlin Heidelberg

Abstract

When associated with high blood pressure, type 2 diabetes mellitus is characterised by a high risk of adverse cardiovascular (CV) and renal outcomes. However, both can be effectively reduced by antihypertensive treatment. Current guidelines on the treatment of hypertension emphasize the need to effectively treat high blood pressure in diabetic individuals, but their recommendations differ in terms of the optimal target blood pressure value to aim for in order to maximise CV and renal protection. In some guidelines the recommended target blood pressure values are <140/90 mmHg (systolic/diastolic), whereas in others, blood pressure values close or even less than 130/80 mmHg are recommended. This paper will discuss the evidence for and against a conservative or more aggressive blood pressure target for treated diabetic hypertensive individuals based on the evidence provided by randomised trials, trial meta-analyses and large observational studies. Based on the available evidence, it appears that blood pressure targets will probably have to be lower than <140/90 mmHg, and that values approaching 130/80 mmHg should be recommended. However, evidence in favour of even lower systolic values, i.e. <130 mmHg, is limited and is definitively against a reduction to <120 mmHg.

UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713CrossRefPubMedCentral

Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A (2015) Blood pressure lowering in type 2 diabetes. A systematic review and meta-analysis. JAMA 313:603–615CrossRefPubMed

Bangalore S, Kumar S, Lobach I, Messerli FH (2011) Blood pressure targets in patients with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesan random-effects meta-analyses of randomized trials. Circulation 123:2799–2810CrossRefPubMed

Brunström M, Carlberg B (2016) Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and metanalyses. BMJ 24:352 i717

Thomopoulos C, Parati G, Zanchetti A (2017) Effects of blood pressure lowering treatment on outcome incidence in hypertension: 10. Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 35:922–944CrossRefPubMed

Reboldi G, Gentile G, Angeli F et al (2011) Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 29:1253–1269CrossRefPubMed

American Diabetes Association (2012) Standards of medical care in diabetes – 2012. Diabetes Care 35(Suppl 1):s11–s63

Mancia G, Narkiewicz K, Redón J et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 31:1281–1357CrossRefPubMed

James PA, Oparil S, Carter B et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA 311:507–520CrossRefPubMed

10.

American Diabetes Association (2016) Standards of medical care in diabetes – 2016. Diabetes Care 39(Suppl 1):s1–s112

11.

Rydén L, Grant PJ, Anker SD et al (2014) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes and cardiovascular diseases of the European Society of Cardiology(ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087

12.

Giannattasio C, Failla M, Piperno A et al (1999) Early impairment of large artery structure and function in type 1 diabetes mellitus. Diabetologia 42:987–984CrossRefPubMed

13.

Kimoto E, Shoji T, Shinohara K et al (2003) Preferential stiffening of central over periheral arteries in type 2 diabetes. Diabetes 52:448–453CrossRefPubMed

14.

Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187CrossRefPubMed

15.

Zanchetti A, Grassi G, Mancia G (2009) When should antihypertensive drug treatment be initiated and what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 27:923–934CrossRefPubMed

16.

Mancia G, Laurent S, Agabiti-Rosei E et al (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension task force document. J Hypertens 27:2121–2158CrossRefPubMed

17.

Schrier RW, Estacio RO, Esler A, Mehler P (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086–1097CrossRefPubMed

18.

Patel A for the ADVANCE Collaborative Group (2007) Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840CrossRef

19.

Redon J, Mancia G, Sleight P et al (2012) Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET. J Am Coll Cardiol 59:74–83CrossRefPubMed

20.

Mancia G, Kjeldsen SE, Zappe DH et al (2016) Cardiovascular outcomes at different on-treatment blood pressure in the hypertensive patients of the VALUE trial. Eur Heart J 37:955–964CrossRefPubMed

21.

Cooper-DeHoff RM, Gong Y, Handberg EM et al (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304:61–68CrossRefPubMedPubMedCentral

22.

Jamerson K, Weber MA, Bakris GL et al (2008) Benazepril plus amlodipine or hydrochlothiazide for hypertension in high risk patients. N Engl J Med 359:2417–2428CrossRefPubMed

23.

Mancia G, Grassi G (2014) Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. Hypertension 63:29–36CrossRefPubMed

24.

ACCORD Study Group (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585CrossRef

25.

Boehme AK, Esenwa C, Elkind MS (2017) Stroke risk factors, genetics, and prevention. Circ Res 120:472–495CrossRefPubMedPubMedCentral

26.

Odden MC, McClure LA, Sawaya BP et al (2016) Achieved blood pressure and outcomes in the Secondary prevention of Small Subcortical Strokes Trial. Hypertension 67:63–69CrossRefPubMed

27.

PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood pressure lowering regimen among individuals with previous stroke or transient ischaemic attack. Lancet 358:1033–1041CrossRef

28.

Arima H, Anderson C, Omae T et al (2014) Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial. J Neurol Neurosurg Psychiatry 85:1264–1265CrossRef

29.

Margolis KL, O’Connor PJ, Morgan TT et al (2014) Outcomes of combined risk factor management strategies in type 2 diabetes. The ACCORD randomized trial. Diabetes Care 37:1721–1728CrossRefPubMedPubMedCentral

30.

Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J (2009) Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 151:394–403CrossRefPubMed

31.

Hartaigh ÓB, Szymonifka J, Okin PM (2017) Achieving target SBP for lowering the risk of major adverse cardiovascular events in persons with diabetes mellitus. J Hypertens. https://doi.org/10.1097/HJH.0000000000001515

32.

Weber MA, Bakris GL, Hester A et al (2013) Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med 126:501–508CrossRefPubMed

33.

Peterson JC, Adler S, Burkart JM et al (1995) Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Study. Ann Intern Med 123:754–762CrossRefPubMed

34.

Jackson CE, Solomon SD, Gerstein HC et al (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374:543–550CrossRefPubMed

35.

Ishani A, Grandits GA, Grimm RH et al (2006) Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate and hematocrit with 25-year incidence of end-stage renal disease in the Multiple Risk Factor Intervention Trial. J Am Soc Nephrol 17:1444–1452CrossRefPubMed

36.

Schmieder RE, Schutte R, Schumacher H et al (2014) Mortality and morbidity in relation to change in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET AND TRANSCEND studies. Diabetologia 57:2019–2029CrossRefPubMed

37.

Schmieder RE, Mann JF, Schumacher H et al (2011) Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22:1353–1364CrossRefPubMedPubMedCentral

38.

Pascual JM, Rodilla E, Costa JA, Garcia-Escrich M, Gonzales C, Redon J (2014) Prognostic value of miscroalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 64:1169–1174CrossRef

39.

Ismail-Beigi F, Craven TE, O’Connor PJ et al (2012) Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type diabetic patients. Kidney Int 81:586–594CrossRefPubMed

40.

Parving HH, Brenner BM, McMurray JJ et al (2012) Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2201–2213CrossRef

41.

Haller H, Ito S, Izzo JL et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New Engl J Med 364:907–917CrossRefPubMed

42.

Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755–1762CrossRefPubMed

43.

Frattola A, Parati G, Gamba P et al (1997) Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus. Diabetologia 40:1470–1475CrossRefPubMed

44.

Whelton PK, Carey RM, Aronow WS et al (2017) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2017.11.006

45.

Spence JD (2010) Secondary stroke prevention. Nat Rev Neurol 6:477–486CrossRefPubMed

46.

Arima H, Anderson C, Omae T et al (2012) Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial. Stroke 43:1675–1677CrossRefPubMed

47.

Ettehad D, Emdin CA, Kiran A et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957–967CrossRefPubMed

48.

Zanchetti A, Thomopoulos C, Parati G (2015) Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res 116:1058–1073CrossRefPubMed

49.

Mancia G, Grassi G (2002) Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 20:1461–1464CrossRefPubMed

50.

Ambrosioni E, Leonetti G, Pessina A, Rappelli A, Trimarco B, Zanchetti A (2000) Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. J Hypertens 18:1691–1699CrossRefPubMed

51.

Thomopoulos C, Parati G, Zanchetti A (2016) Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs discontinuations because of adverse events-meta-analisys of randomized trials. J Hypertens 34:1451–1463CrossRefPubMed

52.

Hirakawa Y, Arima H, Webster R et al (2016) Risk associated with permanent discontinuation of blood pressure lowering medications in patients with type 2 diabetes. J Hypertens 34:781–787CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Medicine Matters Diabetes

Abstract

Be confident that your patient care is up to date